U.S FDA strengthens warnings on Glaxo, Roche/Biogen cancer drugs
Sept 25 (Reuters) - U.S. regulators strengthened the warning labels on two cancer drugs - GlaxoSmithKline Plc's Arzerra, and Rituxan, made by Biogen Idec Inc and Roche Holding AG - to reflect the risk that they can reactivate the hepatitis B virus in patients previously infected with it.
The U.S. Food and Drug Administration said the risk is already described in the warnings and precautions section of the label for both drugs. Now the information will be placed in a black box, indicating the most serious type of risk.
- Air strike kills 15 civilians in Yemen by mistake: officials
- North Korea executes leader's powerful uncle in rare public purge |
- Twitter backtracks on block feature after users revolt
- Insight: In Yemen, al Qaeda gains sympathy amid U.S. drone strikes
- Pope attacks mega-salaries and wealth gap in peace message